Browse > Article

Evaluation of Vancomycin Use before and after the Computerized Restricted Antibiotic Control Program  

Ahn, Hyo-Cho (College of Pharmacy, Woosuk University)
Lee, Chang-Seop (Department of Internal Medicine, Chonbuk National University Medical School)
Lee, Mi-Kyung (College of Health and Welfare, Woosuk University)
Yang, Jae-Heon (College of Pharmacy, Woosuk University)
Publication Information
YAKHAK HOEJI / v.53, no.3, 2009 , pp. 107-113 More about this Journal
Abstract
Since 2006, the Computerized Restricted Antibiotic Control Program (CRACP) has been incorporated to facilitate a more efficient approval process of vancomycin use at the Chonbuk National University Hospital. The purposes of the study were to evaluate proper use of vancomycin and to examine if there is any improvement when administering the CRACP. The use of vancomycin was retrospectively reviewed by a medical record review based on the American Society of Hospital Pharmacists (ASHP) criteria (i.e., indication, use of critical process indicators and use of outcome measurements) and compared before (Group I) and after the CRACP (Group II). Two hundred fifty six patient records were evaluated (138 in Group I and 118 in Group II). There was a statistically significant improvement in the report of justification for vancomycin use after CRACP (42.0% vs. 62.7%, p=0.001). Out of eight critical process indicators, two indicators (appropriate cultures prior to medication [68.8% vs. 85.6%, p=0.002] and serum vancomycin level measurement [0% vs. 7.6%, p=0.001]) were significantly improved after CRACP. The total incidence of adverse effects was decreased from 14.5% to 6.8%. In addition, there was a statistically significant difference in WBC count reduction within normal range (52.8% vs. 73.1%, p=0.024). The CRACP appears to be a promising approach to improve use of vacomycin in a hospital setting. However, further evaluation for the long-term period should be performed to confirm the performance of the program.
Keywords
vancomycin; antibiotics; drug use evaluation; computerized order system;
Citations & Related Records
연도 인용수 순위
  • Reference
1 CDC : Recommendations for preventing the spread of vancomycin resistance. Recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC). MMWR 44, 1 (1995)
2 Davis, R. L., Smith, A. L. and Koup, J. R. : The "red man's syndrome" and slow infusion of vancomycin. Ann. Intern. Med. 104, 285 (1986)
3 Iwamoto, T., Kagawa, Y. and Kojima, M. : Clinical efficacy of therapeutic drug monitoring in patients receiving vancomycin. Biol. Pharm. Bull. 26, 876 (2003)
4 Ambrose, P. J. and Winter, M. E. : Vancomycin, In: Michael E. Winter. Basic Clinical Pharmacolinetics. 4th Ed. Philadelphia: Lippincott Williams & Wilkins, p451 (2004)
5 Moellering, R. C. : Pharmacokinetics of vancomycin. J. Antimicrob. Chemother. 14, 43 (1984)
6 Fekety, R. : Vancomycin. Med. Clin. North Am. 66, 175 (1982)   DOI
7 Elting, L. S., Rubenstein, E. B., Kurtin, D., Rolston, K. V., Fangtang, J., Martin, C. G., Raad, I. I., Whimbey, E. E., Manzullo, E. and Bodey, G. P. : Mississippi mud in the 1990s: risks and outcomes of vancomycin-associated toxicity in general oncology practice. Cancer 83, 2597 (1998)   DOI   ScienceOn
8 Hughes, W. T., Armstrong, D., Bodey, G. P., Brown, A. E., Edwards, J. E., Feld, R., Pizzo, P., Rolston, K. V., Shenep, J. L. and Young, L. S. : 1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America. Clin. Infect. Dis. 25, 551 (1977)   DOI   ScienceOn
9 Kunin, C. M. : Guidelines for peer review. Veterans Administration Ad Hoc Interdisciplinary Advisory Committee on Antimicrobial Usage. Audits of antimicrobial usage. JAMA 237, 1001 (1977)
10 Cunha, B. A. and Ristuccia, A. M. : Clinical usefulness of vancomycin. Clin. Pharm. 2, 417 (1983)
11 Reginald, F., Captitano, B., Gary, E. and Matzke, R. : Vancomycin. In: John E. Murphy. Clinical pharmacokinetics. 3rd ed. Bethesda, Maryland: the American Society of Health- System Pharmacists Inc., p349 (2005)
12 Khurana, C. and de Belder, M. A. : Red-man syndrome after vancomycin: potential cross-reactivity with teicoplanin. Postgrad. Med. J. 75, 41 (1999)   DOI   PUBMED
13 Gerald, K. McEvoy : AHFS drug information 2006. Bethesda, MD, American Society of Hospital Pharmacists, Inc. p473 (2006)
14 Johnson, C. C. and Tunkel, A. R. : Viridans streptococci, Groups C and G streptococci, and Gemella morbillorum. In: Mandell, G. L., Bennett, J. E. and Dolin, R., eds. Principles and practice of infectious diseases. 6th ed. Vol 2. Philadelphia: Churchill Livingstone, p2434 (2005)
15 Mccormick, M. H., Mcguire, J. M., Pittrenger, G. E., Pittrenger, R. C. and Stark, W. M. : Vancomycin, a new antibiotic. I. Chemical and biologic properties. Antibiot. Annu.3, 606 (1955-1956).   PUBMED
16 CDC. Staphylococcus areus resistant to vancomycin---United States, 2002. MMWR 51, 565 (2002)
17 Pfeiffer, R. R. : Structural features of vancomycin. Rev. Infect. Dis. 3, 205 (1981)   DOI
18 Kucers, A., Crowe, S. M., Grayson, M. L. and Hoy, J. F. : The Use of Antibiotics. A clinical Review of Antibacterial, Antifungal and Antiviral Drugs. Fifth ed., Oxford, Oxford Univ Press, p761 (1977)
19 Cook, F. V. and Farrar, W. E. : Vancomycin revisited. Ann. Intern. Med. 88, 813 (1978)   DOI   PUBMED   ScienceOn